Biomarker Technologies for Cardiovascular Health

Cardiex Limited (ASX:CDX) (the “Company”) is pleased to present its investor presentation.

June 2024 Quarterly Highlights

Record annual company revenues – $12.4m.

• Initial Pulse units arrived in USA & Australia.
• Marketing and demand generation campaigns driving awareness and demand.
• New partnerships and pilot programs.
• Initial Pulse production run increased to 8,000 (previously 3,000).
• Pre-submission phase for OTC FDA-clearance for the Pulse.
• New patent awarded by USPTO for wearable PPG sensor technology.
• Nearing completion of our wearable sensor validation study.
• FDA submission for wearable technology anticipated Q1 25.

Financial Overview (Q4 ending 30 June 2024)

• Revenue and other income for FY24 of $12.4m (FY23 - $6.0m)
• Q4 operating cash outflows of $2.8m, being a significant reduction to the Q3 normalized operating outflows of $3.4m, due to:
  • Higher cash receipts of $0.9m in Q4 vs $0.7m in Q3, and
  • FY23 R&D tax incentive of $0.7m.
• Cash resources and reserves ~ $6.5m, comprising:
  • $0.5m cash; and
  • $6.0m being funded under the Funding Commitment Agreement with C2 Ventures.
• Cash resources are believed to be sufficient to fund the Company’s growth initiatives, its operations, and to meet its business objectives.

Click here for the full ASX Release

This article includes content from CardieX Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.